frontiers in Aging

TYPE Correction
PUBLISHED 19 October 2026
DOI 10.3389/fragi.2026.2016735

Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY
Kieran Reid,
Brigham and Women's Hospital and Harvard Medical School, United States

*CORRESPONDENCE
Tiffany M. Cortes,
cortest@uthscsa.edu

RECEIVED 01 October 2026
REVISED 01 October 2026
ACCEPTED 02 October 2026
PUBLISHED 19 October 2026

CITATION
Dinkla L, Beavers KM, Robbins R, Akpalu D, Wherry SJ, Miller G, Beavers DP, Espinoza S, Trejo J, Stepanenko A and Cortes TM (2026) Correction: Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial *post hoc* analysis.
Front. Aging 7:2016735.
doi: 10.3389/fragi.2026.2016735

COPYRIGHT
© 2026 Dinkla, Beavers, Robbins, Akpalu, Wherry, Miller, Beavers, Espinoza, Trejo, Stepanenko and Cortes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial *post hoc* analysis

Lauren Dinkla[1], Kristen M. Beavers[1], Ronna Robbins[2], Dela Akpalu[3], Sarah J. Wherry[4,5], Gary Miller[1], Daniel P. Beavers[3], Sara Espinoza[6,7,8], Jonathan Trejo[9], Allison Stepanenko[8] and Tiffany M. Cortes[8,10]*

[1]Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, United States, [2]Department of Nutrition and Food Sciences, Texas Woman's University, Denton, TX, United States, [3]Department of Statistical Science, Wake Forest University, Winston-Salem, NC, United States, [4]Division of Geriatric Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, [5]VA Eastern Colorado Geriatric Research, Education, and Clinical Center (GRECC), VA Eastern Colorado Healthcare System, Aurora, CO, United States, [6]Center for Translational Geroscience, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States, [7]Diabetes and Aging Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States, [8]Department of Medicine, UT Health San Antonio, Sam and Ann Barshop Institute for Longevity and Aging Studies, UT Health San Antonio, San Antonio, TX, United States, [9]Endocrinology Section, South Texas Veterans Healthcare System, San Antonio, TX, United States, [10]San Antonio Geriatric Research, Education, and Clinical Center (GRECC), South Texas Veterans Healthcare System, San Antonio, TX, United States

KEYWORDS
glucagon-like peptide-1 receptor agonist, randomized controlled trial, older adults, bone mineral density, bone turnover

A Correction on
Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial *post hoc* analysis

by Dinkla L, Beavers KM, Robbins R, Akpalu D, Wherry SJ, Miller G, Beavers DP, Espinoza S, Trejo J, Stepanenko A and Cortes TM (2025). Front. Aging 6:1691007. doi: 10.3389/fragi.2025.1691007

There was a mistake in Table 1 as published. The column headers for the study arms were transposed: the baseline data displayed under Semaglutide + Lifestyle Counseling belong to Lifestyle Counseling Alone, and *vice versa*. The corrected Table 1 appears below.

The original version of this article has been updated.

10.3389/fragi.2026.2016735

TABLE 1 Baseline descriptive characteristics of the study sample.

Variable	Overall (n = 20)	Lifestyle counseling alone (n = 10)	Semaglutide + Lifestyle counseling alone (n = 10)
Demographic			
Age (years)	72.7 ± 4.8	73.4 ± 4.9	71.9 ± 5.0
Female, n (%)	10 (50)	5 (50)	5 (50)
White, n (%)	18 (90)	9 (90)	9 (90)
Hispanic, n (%)	9 (45)	4 (40)	5 (50)
Education			
Greater than high school, n (%)	18 (90)	10 (100)	8 (80)
Marital status			
Married, n (%)	12 (60)	7 (70)	5 (50)
Body composition			
Weight (kg)	91.8 ± 16.4	95.7 ± 16.0	87.8 ± 16.7
Body mass index (kg/m^2)	32.9 ± 4.0	34.1 ± 3.7	31.8 ± 4.1
Presence of comorbidity, n (%)			
Diabetes	6 (30)	5 (50)	1 (10)
Prediabetes	14 (70)	5 (50)	9 (90)
Hypertension	11 (55)	6 (60)	5 (50)
Osteoporosis	4 (20)	2 (20)	2 (20)
DXA-acquired variables			
Total fat mass (kg)	35.41 ± 7.58	37.71 ± 5.88	33.11 ± 8.65
Total lean mass (kg)	51.74 ± 11.44	53.26 ± 11.36	50.23 ± 11.91
Whole body bone mineral density (g/cm^2)	1.26 ± 0.22	1.33 ± 0.25	1.19 ± 0.16
Lumbar spine bone mineral density (g/cm^2)	1.18 ± 0.34	1.27 ± 0.41	1.09 ± 0.26
Pelvis bone mineral density (g/cm^2)	1.26 ± 0.36	1.39 ± 0.43	1.13 ± 0.22
Leg bone mineral density (g/cm^2)	1.35 ± 0.45	1.51 ± 0.57	1.19 ± 0.22
Biomarkers of bone turnover			
Procollagen type 1 N-terminal propeptide (ug/L)	48.46 ± 26.15	50.01 ± 27.64	46.90 ± 25.96
C-terminal telopeptide of type I collagen (ug/L)	0.28 ± 0.23	0.32 ± 0.28	0.25 ± 0.18

Continuous data are presented as means ± standard deviation, and categorical data are presented as absolute numbers (percentages).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.